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Medulloblastoma is the most frequent malignant brain
tumor in children. Four medulloblastoma molecular sub-
groups, MBSHH, MBWNT, MBGRP3 and MBGRP4, have
been identiﬁed by integrated high-throughput platforms.
Recently, a 22-gene panel NanoString-based assay was
developed for medulloblastoma molecular subgrouping,
but the robustness of this assay has not been widely evalu-
ated. Mutations in the gene for human telomerase reverse
transcriptase (hTERT) have been found in medulloblasto-
mas and are associated with distinct molecular subtypes.
This study aimed to implement the 22-gene panel in a Bra-
zilian context, and to associate the molecular proﬁle with
patients’ clinical-pathological features. Formalin-ﬁxed,
parafﬁn-embedded (FFPE) medulloblastoma samples
(n = 104) from three Brazilian centers were evaluated.
Expression proﬁling of the 22-gene panel was performed
by NanoString and a Canadian series (n = 240) was
applied for training phase. hTERT mutations were ana-
lyzed by PCR followed by direct Sanger sequencing and
the molecular proﬁle was associated with patients’ clinico-
pathological features. Overall, 65% of the patients were
male, average age at diagnosis was 18 years and 7% of the
patients presented metastasis at diagnosis. The molecular
classiﬁcation was attained in 100% of the cases, with the
following frequencies: MBSHH (n = 51), MBWNT (n = 19),
MBGRP4 (n = 19) and MBGRP3 (n = 15). The MBSHH and
MBGRP3 subgroups were associated with older and youn-
ger patients, respectively. The MBGRP4 subgroup
exhibited the lowest 5-year cancer-speciﬁc overall survival
(OS), yet in the multivariate analysis, only metastasis at
diagnosis and surgical resection were associated with
OS. hTERT mutations were detected in 29% of the cases
and were associated with older patients, increased hTERT
expression and MBSHH subgroup. The 22-gene panel pro-
vides a reproducible assay for molecular subgrouping of
medulloblastoma FFPE samples in a routine setting and is
well-suited for future clinical trials.
Key words: hTERT, medulloblastoma, molecular sub-
groups, NanoString.
INTRODUCTION
Medulloblastoma is the most frequent malignant brain
tumor in children, accounting for approximately 20% of
all pediatric intracranial tumors.1,2 Recent estimates of the
occurrence of central nervous system tumors, such as
medulloblastoma, suggest they represent about 2.5% of
the newly diagnosed cases of pediatric neoplasms in Bra-
zil.3 In adults, medulloblastomas are less common, with a
peak of incidence between 20 and 35 years old.4 Advances
in the treatment of medulloblastoma have improved sur-
vival rates over the last few decades. However, the disease
outcome remains very poor, with both 5-year overall and
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event-free survivals for high-risk patients being about
25–44%.5–7
Histologically, medulloblastomas can be classiﬁed as
classic, the most common subtype (70%), followed by the
desmoplastic (10–20%), anaplastic/large-cell subtype
(5–10%) and extensive nodularity subtype (5–10%).5,8
The major prognostic factors are histology, age at diagno-
sis, presence of metastatic disease, and the extent of tumor
volume at resection.9,10 Younger medulloblastoma
patients, who have evidence of metastasis at diagnosis,
residual disease after surgery or large cells/anaplastic his-
tology, are associated with an unfavorable prognosis.9,11,12
Until recently, these clinical and pathological prognostic
factors were used for deﬁning overall disease risk, but
newer combinations of clinical, pathological and molecular
prognostic markers are providing a more accurate disease
risk stratiﬁcation.13
Medulloblastomas can be molecularly classiﬁed based
on speciﬁc genomic and genetic features.14–16 Gene
expression analysis using large cohorts of medulloblasto-
mas has identiﬁed four molecular subgroups of medullo-
blastoma, namely WNT (MBWNT), SHH (MBSHH), group
3 (MBGRP3) and group 4 (MBGRP4).
14,16,17 Moreover, this
molecular classiﬁcation correlates with several clinical-
pathological features, such as patient prognosis, histology
and age at diagnosis.10,17 The MBWNT subgroup has a bet-
ter prognosis, whereas MBGRP3 patients present with a
poor prognosis.18 MBWNT medulloblastomas can occur at
all ages, but are infrequently seen in infants and are more
common in children. The MBGRP4 subgroup is also more
frequent in children, but it can also be seen in both infant
and adult medulloblastoma. MBGRP3 tumors are frequent
in infants and children, but are rare in adults, whereas
MBSHH subgroups are very frequent in both infants and
adults.10,17,19 Thus, subgroup analysis using gene expres-
sion signatures is providing clinicians with a new tool for
improved management of medulloblastoma patients.
In addition to molecular signatures, gene alterations
such as mutations in the promotor region of the gene for
human telomerase reverse transcriptase (hTERT) have
been described in about 20% of medulloblastomas, and
they correlate with a worse prognosis.20 Furthermore, the
presence of hTERT promoter mutations is associated with
a higher expression of hTERT gene in medulloblastomas,
especially in non-infant MBSHH.
20–22
The nCounter® system (NanoString Technologies,
Seattle, WA, USA) is an automated high-throughput plat-
form designed to evaluate mRNA expression. The mRNA
expression levels are directly measured with a high sensi-
tivity in a single multiplexed hybridization reaction.23 The
nCounter® platform is particularly well-suited for expres-
sion analysis of formalin-ﬁxed, parafﬁn-embedded (FFPE)
samples, as the quality of these samples may be highly
variable, producing low yields of highly degraded
mRNA.24 Furthermore, the nCounter® technology does
not require further validation, since it does not require
enzymatic reactions, it generates reproducible results.23
Northcott and colleagues constructed a 22-gene panel that
could accurately distinguish medulloblastoma molecular
subgroups using the nCounter® platform. The 22 genes
they selected have differential expressions associated with
each molecular subgroup.25
The aim of the present study was to implement the
22-gene panel for molecular classiﬁcation of medulloblas-
tomas from FFPE blocks using the nCounter® technology
in a Brazilian population, and to associate the molecular
subgroups with the hTERT mutational status and clinical-
pathological features of our cohort.
MATERIAL AND METHODS
Patients
Brazilian cases
A series of 104 patients with medulloblastoma were
retrieved between 1995 and 2017 from three Brazilian ref-
erence centers: the Barretos Cancer Hospital (BCH),
Ribeirao Preto Medical School of University of Sao Paulo
(FMRP-USP); and Universidade Federal de São Paulo
(UNIFESP). In two cases (patients #87 and #98;
Table S1), we assessed both primary and metastatic tis-
sues. The histologic diagnoses of all cases were reviewed
by two expert neuropathologists in accordance with
revised 2016 WHO classiﬁcation, which has histologically
deﬁned medulloblastomas as classic, desmoplastic/nodular,
extensive nodularity or large cell/anaplastic.26 The sum-
mary of clinical-pathological and molecular features is
presented in the Table S1. This study was approved by the
local ethics committee (#478/2011).
Canadian series
The molecular data of a series comprising 240 medulloblas-
tomas from the Hospital for Sick Children, University of
Toronto, Canada, was kindly provided by Dr. Michael
Taylor, and were employed for class prediction.25
RNA isolation
RNA was isolated from three to ﬁve 10-μm-thick sections
using RNeasy Mini kit (Qiagen, Venlo, Netherlands) fol-
lowing the manufacturer’s instructions. Brieﬂy, following
deparafﬁnization steps, unstained slides were scraped
upon a tumor area demarcated on a HE slide. All speci-
mens were submitted to protease digestion followed by
nucleic acid isolation followed by DNAse digestion and
sample elution. RNA concentrations were assessed by
spectrophotometry (NanoDrop; Thermo Fisher Scientiﬁc,
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Waltham, MA, USA) and a subset of samples were also
evaluated by BioAnalyzer (Agilent Technologies, Inc.,
Santa Clara, CA, USA).
The nCounter® system (NanoString)
The medulloblastoma panel was carried out using the
NanoString nCounter Elements™. The custom CodeSet was
designed using characteristic genes for each medulloblas-
toma subgroup as previously employed: MBSHH – PDLIM3,
EYA1, HHIP, ATOH1, SFRP1; MBWNT – WIF1, TNC,
GAD1, DKK2, EMX2; MBGRP3 – IMPG2, GABRA5,
EGFL11, NRL, MAB21L2, NPR3; MBGRP4 – KCNA1,
EOMES, KHDRBS2, RBM24, UNC5D, OAS1 and three
housekeeping genes (ACTB, GAPDH and LDHA).25 In
addition, 11 other cancer genes including hTERT gene were
added to the gene panel CodeSet used in this study. The
expression analysis of the hTERT gene was performed
for the present study and the analyses of the other
10 genes will be further reported (manuscript in prepara-
tion). All procedures regarding sample preparation,
hybridization, detection and scanning were performed
according to the manufacturer’s instructions (NanoString
Technologies, Seattle, WA, USA).
The custom probes (A and B) were designed by IDT
(IDT Technologies), containing 35–50 base pairs each
and probes were diluted to a ﬁnal concentration of
0.6 nmol/L (probe A) and 3.0 nmol/L (probe B) to create
the working probe pools. A total amount of 100–300 ng
RNA was hybridized with probe pools, hybridization
buffer and TagSet reagents and incubated at 67 C for
21 h. Then, samples were loaded to the nCounter®
PrepStation (NanoString), which automatically performs
puriﬁcation steps and cartridge preparation. Finally, the
cartridges containing immobilized reporter complexes
were transferred to nCounter® Digital Analyzer
(NanoString), a high-resolution setting, which captures up
to 280 ﬁelds of view (FOVs) per sample providing all gene
counts.
DNA isolation and hTERT mutational analysis
DNA was isolated from three to ﬁve sections each 10 μm
thick using QIAmp DNA Mini kit (QIAgen) as previously
reported.20 DNA concentrations were assessed by spectro-
photometry (NanoDrop).
hTERT promoter hotspot mutations (−124 bp G > A
and -146 bp G > A) were screened by PCR followed by
Sanger sequencing as previously described.20,27 All sam-
ples with mutations were conﬁrmed at least twice.
Data analysis
Reporter probe counts were captured by nCounter® Digital
Analyzer and raw data was collected and pre-processed by
nSolver™ Analysis Software v3.0 (NanoString). For data
normalization, NanoStringNorm package was employed (ver-
sion 18 November, 2015; http://cran.r-project.org/web/
packages/NanoStringNorm).28 The normalization method
basically consists of four major corrections, which are probe-
level background correction, code-count normalization, back-
ground correction and sample content normalization by
housekeeping genes. The NanoStringNorm package
uncovers potential batch-effects, identiﬁes background arti-
facts and assesses negative/positive controls. Each parameter
for all normalizations is associated with plots and all results,
diagnostics and expression values were outputted for statisti-
cal analyses, heatmaps design and use in class prediction
methodologies.
For class prediction analysis of the Brazilian series
(n = 104), the Canadian series (n = 240) was employed to
establish a prediction dataset, since all samples had been
previously classiﬁed for medulloblastoma molecular sub-
groups.25 Raw data from all samples (Brazilian and Cana-
dian series) were normalized and the gene expression
values were deﬁned. Normalized data were input for class
prediction analysis using the Prediction Analysis for
Microarrays (PAM) algorithm.29 PAM is a statistical tech-
nique for class prediction from gene expression data using
nearest shrunken centroids. Class prediction was per-
formed using a machine learning method following these
analytical phases: (i) training phase: data from Canadian
series were considered for input by pairing with the
expected output to train our model employing the PAM
algorithm; (ii) validation phase: data from the Brazilian
series employing the heatmap clustering as gold-standard
were used for initial classiﬁcation of medulloblastoma
molecular subgroups applying the PAM method; (iii) test
phase: application of our model to the Brazilian series for
class prediction and probability results.
For analysis of hTERT mRNA expression, Mann-
Whitney test was applied for comparing wild-type and
hTERT mutated cases. Survival analysis was carried out
by Kaplan–Meier curves, which were compared by the
log-rank test. For disease-speciﬁc overall survival (OS),
patients who were lost to follow-up were censored con-
sidering their last follow-up visit, and patients who died
due to external causes or surgical complications were
censored considering death date as the last data entry.
For all analyses, cancer-speciﬁc death was considered as
the unfavorable event.
For pre-processing and normalization, statistical ana-
lyses, graph constructions, heatmap designs and class
© 2018 Japanese Society of Neuropathology
NanoString assay for medulloblastoma 477
prediction, the KNIME v.3.2.0 software (KNIME
GmbH, Konstanz, Germany) was employed in the R
environment (R Foundation, Vienna, Austria). For sur-
vival analysis, the IBM SPSS Statistics for Windows ver-
sion 21.0 (IBM, Armonk, NY, USA) and GraphPad
Prism version 6.0 (GraphPad Software, San Diego, CA,
USA) were employed. A Cox multivariate analysis con-
sidering age and gender as confounders was performed
for disease-speciﬁc OS analysis. The level of signiﬁcance
for all analyses was 5%.
RESULTS
Clinicopathological features of Brazilian patients
We evaluated 104 tumors from patients diagnosed with
medulloblastoma (Table 1; Table S1). Thirty-six (35%)
patients were female and 67 (65%) were male (data were
unavailable from one patient). The average age at diagno-
sis was 18 years old (range, 2–56 years), with 11 patients
≤ 4 years old, 55 cases between 5 and 19 years old, and
37 more than 20 years old (no available information for
one patient). Clinical ﬁndings showed that 93% of the
patients (92/99) did not have metastasis at diagnosis,
whereas 7% (7/99) of the patients presented metastasis at
diagnosis (data were not available for ﬁve cases). Addi-
tionally, 63% of the patients (59/94) underwent total surgi-
cal resection and 37% (35/94) partial surgical resection. For
two patients, surgery was not performed and they were sub-
jected to biopsy only (data were not available for eight
cases). Histologic classiﬁcation showed that 57% (59/104)
had classic histology, 24% (25/104) desmoplastic/nodular
histologic features, 4% (4/104) anaplastic/large cells, and
12% (13/104) extensive nodularity, and 1% (1/104) mixed
histology. One case was not clearly deﬁned and one case
presented inconclusive histological features (Table 1;
Table S1).
Overall survival was associated with metastasis at diag-
nosis (P = 0.04) and surgical resection (P = 0.001;
Table S2).
Classiﬁcation of medulloblastoma molecular
subgroups
We obtained conclusive results from all 106 FFPE samples
that comprised 104 primary samples and two metastatic
samples. We initially performed an unsupervised cluster-
ing to generate heatmaps (Figure S1). The Canadian series
provided the known class predictions for comparison to
the subgroup ﬁndings from the Brazilian cohort.25 Follow-
ing normalization of raw data from both series (Canadian
series combined with the Brazilian series; Figure S1), the
PAM method was applied for class prediction. Employing
a machine learning approach, we successfully classiﬁed all
medulloblastoma samples according to molecular sub-
groups (Figs 1, 2A). The probability of each subgroup for
all samples and the highest probability index for speciﬁc
molecular subgroups was considered for the ﬁnal classiﬁ-
cation. Most samples in each subgroup presented a proba-
bility rate higher than 90%. Therefore, the ﬁnal
proportions for classiﬁcation of the Brazilian medulloblas-
toma subgroups was 49% MBSHH (n = 51), 18% MBWNT
(n = 19), 14% MBGRP3 (n = 15) and 18% MBGRP4
(n = 19) (Figs 1, 2A; Table 1).
Interestingly, for the two patients (patients #87 and
#98; Table S1) in which both primary and metastatic tissue
could be evaluated, each pair exhibited the same molecu-
lar proﬁle (MBSHH).
Association of molecular subgroups with
clinicopathological features
Clinical and molecular features of the molecular subgroup
are summarized in Table 1 and described in detail in
Table S1. Older age patients were strongly associated wit-
h the MBSHH subgroup and younger patients with
MBGRP3 (P < 0.0001; Table 1). No association by age cat-
egory (< 4, 5–19 and > 20 years) and disease outcome was
observed (P = 0.1). The female gender was strongly asso-
ciated with MBWNT (P < 0.0001; Table 1).
Table 1 Clinical and molecular characteristics of Brazilian cohort according to the medulloblastoma molecular subgroups
MB molecular
subgroup
n Average age (range) F/M
ratio
Histology† hTERT
mutation
Classic Anaplastic/
large cells
Extensive
nodularity
Nodular/
desmoplastic
% Mutated
cases
MBSHH 51 24 years (2–56 years) 1:2.4 20 2 3 24 77 17
MBWNT 19 13 years (4–27 years) 3.75:1 13 0 5 0 9 2
MBGRP3 15 8 years (4–17 years) 1:6.5 10 2 2 1 9 2
MBGRP4 19 13 years (4–32 years) 1:3.75 16 0 3 0 5 1
All 104 18 years (2–56 years) 1:1.6 59 4 13 25 29 22/76
†One case from MBSHH was classiﬁed as Mixed, one case was not possible to classify, and one case no data were available. MB, medulloblas-
toma; n, number of cases; F, female; M, male.
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Univariate analysis indicated a trend of association
between disease-speciﬁc OS and medulloblastoma molecu-
lar subgroup (log-rank test: P = 0.07; Fig. 2B; Table S2).
The highest 5-year disease-speciﬁc OS was observed for
the MBWNT (100%) subgroup, followed by MBGRP3
(73%), MBSHH (64%) and MBGRP4 (63%).
Multivariate analysis showed a higher hazard ratio
(HR) for patients who underwent partial surgical re-
section (HR = 3.73, P = 0.006; Table 2), but no increased
HR was observed for age, gender, metastasis at diagnosis,
or for molecular subgroup (Table 2).
hTERT mutational status
Hotspot hTERT promoter mutations (−124 bp G > A and
-146 bp G > A) were successfully sequenced in 73.1%
(76/104) of tumors. Of these, 29% (22/76) of the cases were
mutated (Fig. 3A), with 82% (18/22) harboring the -124 bp
G > A mutation and 18% (4/22) the -146 bp G > A muta-
tion. The frequency of hTERT mutations was signiﬁcantly
higher in the MBSHH subgroup (77%), than in MBWNT
(9%), MBGRP4 (9%), and MBGRP4 (5%) (p = 0.002;
Table 1; Table S1). The distribution of hTERT mutation
was associated with older age as follows: 4.5% (1/22) of
mutated cases in patients ≤ 4 years old, 36.4% (8/22) of
mutated cases between 5 and 19 years old, and 59.1%
(13/22) of mutated cases in patients more than 20 years old
(P = 0.002). We extended our analysis to determine
whether hTERT mutational status correlated with hTERT
gene expression assessed in the NanoString gene panel, and
we found that hTERT mutated tumors exhibited a signiﬁ-
cantly increased hTERT expression (P = 0.03; Fig. 3B).
Since most of the hTERT mutated cases belonged to the
MBSHH subgroup, we also evaluated whether hTERT
mutational status and hTERT expression correlated with
OS in this speciﬁc subgroup, but no association was
observed (P = 0.41 and 0.31, respectively). Moreover, nei-
ther hTERT mutational status nor hTERT expression was
associated with OS (P = 0.34 and P = 0.72, respectively;
Fig. 3C, D).
DISCUSSION
Four major medulloblastoma molecular subgroups
(MBWNT, MBSHH, MBGRP3, MBGRP4) have been described
based on speciﬁc molecular characteristics, such as muta-
tions and differential expressions of key genes.14–17,30 The
assignment of medulloblastoma molecular subgroups plays
an important role in patient prognostication,30,31 and may
also be crucial in the design of potential targeted thera-
pies. Herein, we have successfully implemented an effec-
tive approach for medulloblastoma molecular subgrouping
using FFPE from 104 cases from Brazilian health centers.
Additionally, we reported the main clinical and molecular
characteristics for each molecular subgroup.
The molecular pathogenesis of medulloblastomas has
been partially elucidated by microarray expression proﬁl-
ing and, until recently, this high-throughput technique was
the best approach in determining medulloblastoma molec-
ular subgroups.14,15,30 However, these earlier platforms
required large amounts of high-quality RNA, presented a
high variability and are expensive, limiting their applica-
tion as a routine diagnostic approach. Since there is no
current gold-standard method for medulloblastoma molec-
ular subgrouping, the implementation of a robust and inex-
pensive method is urgently needed. For this reason,
Fig. 1 Heatmap clustering of the Brazilian series (n = 104). On the top and on the right side, each colored column represents a medul-
loblastoma subgroup: MBSHH, red; MBWNT, blue; MBGRP4, purple; MBGRP3, green. Lower right color squares: gene expression scaling
from dark blue (−0.4) to dark red (+0.4), with red: increased gene expression; blue: decreased gene expression; white: no differential
expression.
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Dr. Taylor’s group developed the 22-gene panel for the
assignment of medulloblastoma molecular subgroups
employing an innovative platform (nCounter® system;
NanoString) applied to FFPE samples, which are routinely
collected for histopathological analysis.25
For actual assignment of the medulloblastoma molecu-
lar subgroups based on high-throughput gene expression,
it is necessary to employ class prediction analysis. Several
algorithms were previously tested by Dr. Taylor’s group
and the PAM method presented the best scoring index
with the lowest misclassiﬁcation rates compared with other
statistical approaches.25 This method is faster and can
improve accuracy by reducing the effect of intrinsic noise
from highly expressed genes, providing easily interpret-
able results for biologists and clinicians.29 For this reason,
the PAM method was employed for class prediction in the
present study. The gene expression analysis employing the
nCounter® technology using the 22-gene panel together
with the PAM method for class prediction could classify
according to molecular subgroups all medulloblastoma
samples analyzed. We also observed the concordance of
molecular subgroups in paired primary and metastatic tis-
sues in two patients in accordance with previous data.32 In
our series, the majority of cases (49%) were classiﬁed in
the MBSHH subgroup, followed by MBWNT (18%),
MBGRP4 (18%) and MBGRP3 (14%). These frequencies
differ slightly from the reported series, that reported
higher frequencies of MBGRP3 (20–26%) and MBGRP4
(35–37%), which could be explained, at least in part, by
the older age (18 years average) of our cohort in compari-
son with other studies.25,31
Fig. 2 (A) Medulloblastoma molecular subgroup distributions.
Data derived from the Brazilian series (n = 104). In this circle
chart each colored segment represents a medulloblastoma sub-
group: MBSHH, red; MBWNT, blue; MBGRP4, purple; MBGRP3,
green. (B) Disease-speciﬁc overall survival. Kaplan–Meier curves
of overall survival data derived from 99 available patients in the
Brazilian series and expressed according to the medulloblastoma
molecular subgroups. Cumulative survival as a percentage is
shown on the Y-axis and overall survival in months on the X-axis
(log-rank test: P = 0.07). Live patients, patients who were lost fol-
low up or patients who died due to non-cancer-related causes or
surgical complications were censored.
Table 2 Multivariate proportional hazard analysis on the dis-
ease outcome (disease-speciﬁc overall survival) of the molecular
and clinical characteristics
Variables n HR
(95% CI)
P-value
Age
Age < 4 years 8 Ref. Ref.
Age group 5–19 years 2 40 0.53
(0.16–1.76)
0.30
Age group ≥ 20 years 3 20 0.60
(0.16–2.28)
0.45
Gender
Male 61 Ref. Ref.
Female 20 0.97
(0.45–2.12)
0.94
Surgical resection
Total surgical resection 42 Ref. Ref.
Partial surgical resection 26 3.73
(1.47–9.47)
0.006
Metastasis at diagnosis
Absence of metastasis at
diagnosis
63 Ref. Ref.
Presence of metastasis at
diagnosis
5 0.87
(0.16–4.77)
0.88
hTERT mutational status
hTERT wild-type 48 Ref. Ref.
hTERT mutated 20 1.76
(0.72–4.32)
0.22
Molecular subgroup
MBSHH 31 Ref. Ref.
MBGRP3 11 0.91
(0.25–3.26)
0.88
MBGRP4 17 0.88
(0.25–3.15)
0.84
MBWNT 9 0.00 () 0.97
Reference categories: Gender male; molecular subgroup MBSHH.
†MBWNT was not possible to estimate because no event (death) was
observed for this subgroup (disease-speciﬁc overall survival = 100%).
P-values are from Cox proportional hazards analysis. HR, hazard
ratio; 95% CI, 95% conﬁdence interval; Ref, reference category.
© 2018 Japanese Society of Neuropathology
480 LF Leal et al.
Hotspot hTERT somatic mutations have been reported
in medulloblastomas with frequencies ranging
4–27%.20–22,33,34 In the present study, hTERT mutations
were observed in 29% of the cases, and these mutations
were more frequent in MBSHH as previously described
21,22
Moreover, hTERT mutations were associated with older-
aged patients in accordance with previous studies.20,35
Since hTERT-activating promoter mutations are reported
to enhance telomerase expression,27 we included the
hTERT gene in the CodeSet of the 22-gene panel for
medulloblastoma molecular subgrouping. Unsurprisingly,
we observed that hTERT mutated cases also exhibited a
higher hTERT expression.
In the current study, no association was observed
between the molecular features (molecular subgroups,
hTERT mutations status and hTERT expression) and OS
in the multivariate analysis. Due to the retrospective and
multicentric nature of this study, patients were not treated
uniformly, which hampers proper outcome analysis.
Our study illustrates the robustness of the NanoString
gene expression proﬁling of FFPE samples, since all
106 cases from different Brazilian institutions provided
reliable subgroup classiﬁcations. This ﬁnding is important
because samples from different institutions are likely to
have different pre-analytic protocols. Of note, most of the
samples in our study had been stored for several years,
some of them for more than 20, leading to high levels of
nucleic acid degradation, as demonstrated by the difﬁcul-
ties identifying mutational status using traditional analyti-
cal methods from the hTERT gene for a subset of cases.
These ﬁndings suggest that molecular proﬁling of the
22-gene panel will be important for future medulloblas-
toma clinical trials utilizing RNA from FFPE samples.
Importantly, in the revised 2016 WHO CNS classiﬁcation,
a meaningful integration of genetic/biological information
with histopathological features is suggested to enable a
more precise medulloblastoma classiﬁcation.26 In this con-
text, the present mRNA-based 22-gene panel accurately
Fig. 3 Analysis of mutation and expression status of hTERT. (A) Nucleotide sequencing of hTERT promotor region showing hotspot
promotor mutations (−124 bp G > A and −146 G > A) identiﬁed in medulloblastoma samples. (B) hTERT mRNA expression in medul-
loblastoma carrying hTERT promotor mutations compared with wild-type ones (n = 76; Mann-Whitney U-test: P = 0.03). (C) Kaplan-
Meier curves of overall survival of medulloblastoma patients presenting tumors carrying hTERT promotor mutations (red line) com-
pared with wilt-type (blue line) ones (log-rank test: P = 0.34). (D) Kaplan-Meier curves of overall survival of medulloblastoma patients
with tumors having either hypoexpression (red line) or overexpression (blue line) of hTERT (log-rank test: P = 0.72).
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discriminates the four genetically deﬁned medulloblastoma
subgroups, which are MBWNT, MBSHH and non-MBWNT/
non-MBSHH (MBGRP3 and MBGRP4).
26,36,37 Yet, in the
update of WHO classiﬁcation, the MBSHH subgroup
should further divided in accordance with TP53 status that
differentiates two different MBSHH disease entities, dis-
playing distinct genetic features, age of diagnosis and
outcome.36–38
Concluding, we successfully implemented the 22-gene
panel originally described by Northcott and colleagues for
medulloblastoma molecular classiﬁcation in a multicenter
Brazilian cohort of FFPE cases employing the nCounter®
technology. Our ﬁndings demonstrate the feasibility of
medulloblastoma molecular subgrouping in a routine clini-
cal testing.
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SUPPORTING INFORMATION
Additional supporting information may be found in the
online version of this article at the publisher’s website:
http://onlinelibrary.wiley.com/doi//suppinfo.
Table S1 Clinical, pathological and molecular characteris-
tics and outcomes of the Brazilian series of medulloblasto-
mas analyzed in the present study.
Table S2 Univariate analysis of disease-speciﬁc overall sur-
vival associated with clinical, pathological and molecular
characteristics of the Brazilian series of medulloblastomas.
Figure S1 Heatmap clustering of Canadian series
(n = 240) class prediction control dataset combined with
the Brazilian cohort series (n = 104). On the top and on
the right side, each colored column represents a medullo-
blastoma subgroup: MBSHH, red; MBWNT, blue; MBGRP4,
purple; MBGRP3, green. Lower right square: gene expres-
sion scaling from dark red to dark blue; red, increased
gene expression; blue, decreased gene expression
(as described in legend to Fig. 1).
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